Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2005
12/21/2005EP1395558B1 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
12/21/2005EP1395555B1 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derativatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
12/21/2005EP1377567B1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
12/21/2005EP1362039B1 Heterocyclic substituted carbonyl derivatives and their use as dopamine d3 receptor ligands
12/21/2005EP1278730B1 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol
12/21/2005EP1265916B1 Therapeutic anti-cytomegalovirus compounds
12/21/2005EP1265859B1 Amidino compounds useful as nitric oxide synthase inhibitors
12/21/2005EP1223915B1 Dry powder compositions having improved dispersivity
12/21/2005EP1218518B1 Dna polymerase lambda and uses thereof
12/21/2005EP1196442B1 Vgf polypeptides and methods of treating vgf-related disorders
12/21/2005EP1196160B1 A synergistic combination: gabapentin and pregabalin
12/21/2005EP1178973B1 Pyrazinyl-piperazine- compounds, their use and preparation
12/21/2005EP1150703B1 Chaperonin 10 and beta-interferon therapy of multiple sclerosis
12/21/2005EP1144431B1 16-hydroxyestratrienes as selective estrogens
12/21/2005EP1066038B1 Use of cabergoline in the treatment of restless legs syndrome
12/21/2005EP0698108B2 Adenoviral vectors of animal origin and use thereof in gene therapy
12/21/2005EP0579819B1 Novel pyridone derivative having an affinity for the angiotensine ii receptor
12/21/2005CN1711256A 4-tetrazolyl-4phenylpiperidine derivatives for treating pain
12/21/2005CN1711252A 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
12/21/2005CN1711251A 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
12/21/2005CN1711235A New phenyl-naphthalene derivatives, and preparation method and drug containing same
12/21/2005CN1711083A Oral mucosa formulation and process for preparing the same
12/21/2005CN1711081A Proline derivatives having affinity for the calcium channel alpha-2-delta subunit
12/21/2005CN1232539C Match of organic medicine and beta-cyclodextrin derivative and its preparing process
12/21/2005CN1232535C GST fusion expression of conotoxin MVII A gene and its use
12/21/2005CN1232532C Fibroblast growth factor-2 analogue, producing process and application thereof
12/21/2005CN1232521C Novel crystal form of 9-substituted hypoxanthine derivatives
12/21/2005CN1232520C Salts of bicyclic N-acylated imidazo-3-amines and imidazo-5-amines
12/21/2005CN1232503C Propenecarboxylic acid amidoxime derivatives, process for preparation thereof, and pharmaceutical compositions containing same
12/21/2005CN1232278C 醒酒口服液 Hot Oral
12/21/2005CN1232262C Eyedrop powder for treating palsy
12/21/2005CN1232252C Retard release preparation containing alpha-lipoic acid (derivatives)
12/21/2005CN1232246C Application of 4-methyl cyclopentadecanone in manufacture of medicine
12/20/2005US6977298 Tricyclic inhibitors of poly(ADP-ribose) polymerases
12/20/2005US6977267 Spiro-hydantoin compounds useful as anti-inflammatory agents
12/20/2005US6977266 Pyridone derivatives having affinity for cannabinoid 2-type receptor
12/20/2005US6977264 For therapy and prophylaxis of obesity, diabetes
12/20/2005US6977263 Chemical compounds
12/20/2005US6977257 Aripiprazole oral solution
12/20/2005US6977158 Mammalian IAP gene family, primers, probes, and detection methods
12/20/2005CA2338206C High affinity ligands for nociceptin receptor orl-1
12/20/2005CA2302412C Aminoalkylphenol derivatives and related compounds
12/20/2005CA2290966C Sertraline salts and sustained-release dosage forms of sertraline
12/20/2005CA2038025C Optically active alkylenedioxybenzene derivatives and their use in therapy
12/18/2005CA2582385A1 Therapeutic formulations for the treatment of beta-amyloid related diseases
12/18/2005CA2504471A1 Pharmaceutical formulations of amyloid inhibiting compounds
12/15/2005WO2005118631A1 Novel protein complex and use thereof
12/15/2005WO2005118618A1 Substituted propane phosphinic acid derivatives
12/15/2005WO2005118582A1 Corneal perception recovery drug containing amide compound
12/15/2005WO2005118576A1 Constrained himbacine analogs as thrombin receptor antagonists
12/15/2005WO2005118571A1 Pyridin-2-one compounds and their use as modulators of the dopamine d3 receptor
12/15/2005WO2005118558A2 Pyrimidine compounds and use thereof
12/15/2005WO2005118547A1 Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics
12/15/2005WO2005118543A1 Kinase inhibitor and use thereof
12/15/2005WO2005118535A1 Substituted pyrrolidine-2-ones
12/15/2005WO2005118070A1 Therapy for multiple sclerosis
12/15/2005WO2005118009A2 Transdermal delivery system for treatment of cognitive disorders
12/15/2005WO2005117922A1 Usage of the plant of genus ampelopsis and extracts thereof for manufacture of medicament and functional food
12/15/2005WO2005117886A1 Adhesive patch
12/15/2005WO2005117550A2 Composition and method for the treatment of tauopathies
12/15/2005WO2004066931A3 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
12/15/2005WO2004062616A3 Method of treating cognitive decline due to sleep deprivation and stress
12/15/2005WO2003062370A3 Multimeric proteins and methods of making and using same
12/15/2005US20050277773 Pyrrolopyrimidine derivatives
12/15/2005US20050277678 5-(4-Fluorophenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole; prostaglandin and cyclooxygenase inhibitor; antiinflammatory, analgesic, and antipyretic agent
12/15/2005US20050277674 opioid receptor ligands such as {4-[3-(1H-indol-3-yl)-pyrrolidine-1-yl]-1-phenyl-cyclohexyl}-dimethylamine dihydrochloride salt, used as analgesics
12/15/2005US20050277673 such as 4-{[4-({[(3-isopropyl-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)carbonyl]amino}methyl)piperidin-1-yl]methyl}tetrahydro-2H-pyran-4-carboxylic acid; serotonin receptor agonist; antidepressant, anxiolytic agent, analgesic, cognition activator; less toxicity, good absorption, and metabolic stability
12/15/2005US20050277671 Benzimidazolone carboxylic acid derivatives
12/15/2005US20050277652 Hepatocyte growth factor receptor inhibitors; Antitumor agents, anticarcinogenic agents, angiogenesis inhibitors; pyrimidine derivatives like Pyrrolidine-1-carboxylic acid [6-(2-fluoro-4-{3-[2-(4-fluorophenyl)acetyl]thioureido}phenoxy)pyrimidin-4-yl]amide
12/15/2005US20050277646 N-[4-({5-(4-fluorophenyl)-4-[4-(trifluoromethyl)phenyl]pyridin-2-yl}oxy)-1,3-benzothiazol-2-yl]acetamide; vanilloid (capsaicin) receptor antagonist/agonist; antiinflammatory, analgesic, antiarthritis, antirheumatic; diseases involving sensory nerve function
12/15/2005US20050277614 Methods for modulating the axonal outgrowth of central nervous system neurons
12/15/2005US20050277606 Administering by direct injection into heart an expression vector comprising a nucleic acid sequence encoding AOP-1 operably linked to a promoter, wherein expression of nucleic acid sequence within cells of heart enhances production of AOP-1, protecting against myocardial cell death
12/15/2005US20050277190 Progenitor cells; differentiation; cloning
12/15/2005US20050277165 Novel treatment
12/15/2005US20050276820 structural modification alters the biological persistence, preferably the biological half-life
12/15/2005US20050274391 Means for weaning people off smoking and alcohol
12/15/2005CA2568773A1 Cis pyrrolidinyl derivatives and their uses
12/15/2005CA2568524A1 Modulators of muscarinic receptors
12/15/2005CA2568213A1 Composition and method for the treatment of tauopathies
12/15/2005CA2568158A1 Treatment of amyotrophic lateral sclerosis
12/15/2005CA2567909A1 Benzoxazolone derivatives, processes for preparing them and their uses
12/15/2005CA2567489A1 Pyridin-2-one compounds and their use as modulators of the dopamine d3 receptor
12/15/2005CA2566979A1 Use of a cd20 antibody in treatment of multiple sclerosis
12/15/2005CA2566594A1 Butyrylcholinesterase selective inhibitors
12/15/2005CA2566518A1 Compositions and methods using same for treating neurodegenerative disorders
12/15/2005CA2565689A1 Substituted pyrrolidine-2-ones
12/15/2005CA2565326A1 Tetrasubstituted imidazole derivatives as cannabinoid cb1 receptor modulators with a high cb1/cb2 receptor subtype selectivity
12/14/2005EP1605040A1 Monocyte-origin multipotent cell momc
12/14/2005EP1604982A1 Intermediates for the preparation of piperidine derivatives useful as modulators of chemokine receptor activity
12/14/2005EP1604979A1 2-oxo-1-pyrrolidine derivative and its pharmaceutical uses
12/14/2005EP1604970A1 2-(Biphenyl-3-yl)-carboxylic acids of gamma-secretase-modulating activity
12/14/2005EP1604686A1 Use of phenserine and a HMG CoA reductase inhibitor for delaying Alzheimer's disease progression
12/14/2005EP1604681A1 Use of botulinum toxin in the treatment of joint pain
12/14/2005EP1604680A1 Use of botulinum toxin in the treatment of neuralgia pain
12/14/2005EP1604679A1 Use of botulinum toxin in the treatment of visceral pain
12/14/2005EP1604678A1 Use of botulinum toxin in the treatment of post-operative pain
12/14/2005EP1604658A2 Pharmaceutical composition comprising ibuprofen and prochlorperazine
12/14/2005EP1604655A1 Novel use of peptide compounds for treating pain in trigeminal neuralgia
12/14/2005EP1604654A1 Novel use of peptide compounds for treating dyskinesia
12/14/2005EP1604646A1 Viscous compositions containing carbon dioxide
1 ... 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 ... 1833